- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03491436
Pregnancy Remote Monitoring of Women at Risk for Gestational Diabetes
Background: Remote monitoring (RM) is a new screenings- and or diagnostic tool in healthcare. In 2015, the PREMOM study (Pregnancy Remote Monitoring), in which patients with gestational hypertensive diseases did received a RM prenatal follow up, has started. The first results showed an added value of RM in the prenatal follow-up. Due to these results, a RM program for pregnant women with gestational diabetes mellitus (GDM) will be developed and evaluated.
Protocol: Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips. The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
The women is asked to perform four glycemie controls/day (sober and two hours after every mail) with the received glucose monitor. The monitor is connected via Wi-Fi and Bluetooth with the computer of the researches who controls and evaluated these data. Additionally, the pregnant women has to check daily her body weight with a weight scale of her own. They have to upload these data manually in the app on her smartphone.
When the pregnant women has an prenatal consultation, an overview with the data will be send to the responsible gynecologist. The gynecologist will also be alarmed when the pregnant women has three abnormal values at the same moment of the day (ex. Every morning after breakfast). When necessary, advice among life-style can be given or a referral to an endocrinologist can be made. The researches will not perform interventions by herself, only the responsible doctor can do this.
By analyzing the patients parameters when she's at home, a better vision can be achieved of the health of the mother and the child. This study will be conducted as a first research to get a better insight in the added value of RM in pregnancies complicated with GDM.
Study Overview
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Genk, Belgium, 3600
- Ziekenhuis Oost-Limburg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- women with confirmed GDM or at risk for this disease. Pregnancies > 10 weeks of gestation, primipara and multipara.
Exclusion Criteria:
- pregnancies < 10 weeks of gestation, congenital malformations of the fetus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remote monitoring group
Women (at risk of) GDM will be included in this study.
They receive a iHealth Align (a glucose monitor) and associated glycemiestrips.
The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
|
remote monitor glucometer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood glucose sober
Time Frame: an average of 30 weeks
|
The women is asked to perform four glycemie controls/day (sober and two hours after every mail) with the received glucose monitor. The monitor is connected via Wi-Fi and Bluetooth with the computer of the researches who controls and evaluated these data. Has both mother and child advantages when the mother is screened and provided with the remote monitoring devices? is RM acceptable to use in the prenatal care for GDM and does it have in added value in gestational outcomes? |
an average of 30 weeks
|
Weight once a day
Time Frame: an average of 30 weeks
|
the pregnant women has to check daily her body weight with a weight scale of her own. They have to upload these data manually in the app on her smartphone. Has both mother and child advantages when the mother is screened and provided with the remote monitoring devices? is RM acceptable to use in the prenatal care for GDM and does it have in added value in gestational outcomes? |
an average of 30 weeks
|
blood glucose 2 hours after meal 1
Time Frame: an average of 30 weeks
|
The women is asked to perform four glycemie controls/day (sober and two hours after every mail) with the received glucose monitor. The monitor is connected via Wi-Fi and Bluetooth with the computer of the researches who controls and evaluated these data. Has both mother and child advantages when the mother is screened and provided with the remote monitoring devices? is RM acceptable to use in the prenatal care for GDM and does it have in added value in gestational outcomes? |
an average of 30 weeks
|
blood glucose 2 hours after meal 2
Time Frame: through study completion
|
The women is asked to perform four glycemie controls/day (sober and two hours after every mail) with the received glucose monitor. The monitor is connected via Wi-Fi and Bluetooth with the computer of the researches who controls and evaluated these data. Has both mother and child advantages when the mother is screened and provided with the remote monitoring devices? is RM acceptable to use in the prenatal care for GDM and does it have in added value in gestational outcomes? |
through study completion
|
blood glucose 2 hours after meal 3
Time Frame: an average of 30 weeks
|
The women is asked to perform four glycemie controls/day (sober and two hours after every mail) with the received glucose monitor. The monitor is connected via Wi-Fi and Bluetooth with the computer of the researches who controls and evaluated these data. Has both mother and child advantages when the mother is screened and provided with the remote monitoring devices? is RM acceptable to use in the prenatal care for GDM and does it have in added value in gestational outcomes? |
an average of 30 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wilfried Gyselaers, prof. dr., Hasselt University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRM-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Diabetic
-
Acibadem UniversityCompletedPregnancy Related | Diabetic Pregnancy | Complement System; DisorderTurkey
-
Sisli Hamidiye Etfal Training and Research HospitalCompletedPulmonary Aspiration | Fasting | Gastric Volume | Diabetic Pregnancy | Gastric UltrasonographyTurkey
-
Marwa Mohamed FaragCompletedInfant of Diabetic MotherEgypt
-
Assiut UniversityNot yet recruitingInfant of Diabetic Mother
-
University of MinnesotaRecruitingInfant of Diabetic MotherUnited States
-
Eli Lilly and CompanyTerminatedDiabetic Nephropathy | Diabetic Kidney Disease | Diabetic GlomerulosclerosisIsrael, Hungary, United States, Australia, France, Czechia, Puerto Rico
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
Shanghai University of Traditional Chinese MedicineShanghai Jiao Tong University Affiliated Sixth People's HospitalCompletedDiabetic Nephropathy Type 2China
-
University of SaskatchewanUnknownHypoglycemia | Infant, Newborn, Diseases | Pregnancy in Diabetics | Infant, Diabetic Mother | Infant, Large for Gestational AgeCanada
-
NephroGenex, Inc.Medpace, Inc.; Collaborative Study Group (CSG)TerminatedDiabetic Nephropathy | Diabetic Kidney DiseaseUnited States, Australia, Bulgaria, France, Germany, Hong Kong, Hungary, Israel, Mauritius, Poland, Puerto Rico, Spain
Clinical Trials on iHealth Align
-
University of Colorado, DenverNational Cancer Institute (NCI); Icahn School of Medicine at Mount SinaiCompletedCancerUnited States
-
University of California, San FranciscoLivongo HealthCompleted
-
University of Colorado, DenverKaiser PermanenteCompletedAdvanced Medical IllnessUnited States
-
St. Jude Children's Research HospitalCompleted
-
Leslie Balcazar De MartinezCompletedGestational Diabetes MellitusUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteInstitut d'Investigació Biomèdica de Girona Dr. Josep Trueta; Hospital Universitari... and other collaboratorsCompletedFemale Stress Urinary IncontinenceSpain
-
Hasselt UniversityZiekenhuis Oost-LimburgRecruitingGestational Diabetes | TelemonitoringBelgium
-
Rutgers, The State University of New JerseyCompleted
-
Stanford UniversityVarian Medical SystemsTerminatedHead and Neck CancerUnited States
-
William Beaumont HospitalsTerminatedFibrosis, Liver | Cirrhosis, Liver | Steatohepatitis, Nonalcoholic | Fatty Liver DiseaseUnited States